nitric oxide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
=== Claisen condensation and related reactions === Esters can undergo a variety of reactions with carbon nucleophiles. They react with an excess of a Grignard reagent to give tertiary alcohols. Esters also react readily with enolates. In the Claisen condensation, an enolate of one ester (1) will attack the carbonyl group of another ester (2) to give tetrahedral intermediate 3. The intermediate collapses, forcing out an alkoxide (R'O−) and producing β-keto ester 4.
=== Recreational use === A herbal remedy called Krypton was found to contain kratom leaf powder and desmetramadol. Krypton was reportedly linked to at least 9 accidental opioid overdose deaths in Sweden during 2010–2011.
The vaccine was originally developed from Mycobacterium bovis, which is commonly found in cattle. Although it has been weakened, it is still live. The BCG vaccine was first used medically in 1921. It is on the World Health Organization's List of Essential Medicines. As of 2004, the vaccine is given to about 100 million children per year globally. However, it is not commonly administered in the United States.
Sources: en.wikipedia.org
=== Phylogenetics and modern definition === By the early 21st century, vertebrate paleontologists were beginning to adopt phylogenetic taxonomy, in which all groups are defined in such a way as to be monophyletic; that is, groups which include all descendants of a particular ancestor. The reptiles as historically defined are paraphyletic, since they exclude both birds and mammals. These respectively evolved from dinosaurs and from early therapsids, both of which were traditionally called "reptiles". Birds are more closely related to crocodilians than the latter are to the rest of extant reptiles. Colin Tudge wrote:
Banting was born on November 14, 1891, in his family's farmhouse 3.2 km (2 mi) from Alliston, Ontario. He was the youngest of five children of William Thompson Banting, a farmer in New Tecumseth, and Margaret Grant, the daughter of a mill manager. The Bantings were a financially stable family of British and Northern Irish origin. Banting's distant relative, the London-based undertaker William Banting, popularised a weight-loss diet in 1864, and the word "Banting" entered the Oxford English Dictionary as its description. His mother's relatives, the Grants, were of Scottish descent. With his family being located within a secure rural community, Banting was raised in prosperous circumstances. He was often called "Fred" or "Freddie." Farm life largely defined most of his boyhood. He felt excluded from his siblings, all multiple years his senior, and recalled that "my older brothers could not be bothered with me for the most part." When he began schooling at the age of seven, Banting was a shy, asocial boy who tired of the attendance and was bullied frequently. Early difficulties with spelling ensured poor marks in exams: "I simply could not spell. Every word seemed to have about three ways of spelling. It was a guess and I invariably guessed wrong." He later attributed these experiences as being the product of an inferiority complex. During his childhood, Banting devoted himself to farmwork, grew close with his mother, and sympathised with animals in the absence of other company.
== Antimicrobial peptides == Antimicrobial Peptides (AMPs) have gained attention because they are much less susceptible to the development of microbial resistance. Other antibiotics may be susceptible to bacterial resistance, like multi-resistant staphylococcus aureus (MRSA) which is known as a common relic in the healthcare industry while other bacterial strains have become more of a concern for waste water treatment in local rivers or bays. AMPs can be functionalized onto a surface by either chemical or physical attachment. AMPs can be physically attached by using oppositely charged polymeric layers and sandwiching the polypeptide between them. This may be repeated to achieve multiple layers of AMPs for the recurring antibacterial activity. There are a few drawbacks to this mechanism. Assembly thickness and polymer-peptide interactions can affect the diffusion of peptide to bacterial contact. Further research should be carried out to determine the effectiveness of the adsorption technique. However, the chemical attachment of AMPs is also widely studied. AMPs can be covalently bound to a surface, which minimizes the "leaching effect" of peptides. The peptide is typically attached by a very exergonic chemical reaction, thus forming a very stable antimicrobial surface. The surface can be functionalized first with a polymer resin such as polyethylene glycol (PEG). Recent research has focused on producing synthetic polymers and nanomaterials with similar mechanisms of action to endogenous antimicrobial peptides.
==== On-farm efficiency ==== On-farm, precision agriculture technologies can minimize inputs required for a given yield. For example, variable-rate application (VRA) technologies can apply precise amounts of water, fertilizer, pesticide, herbicide, etc. A number of empirical studies find that VRA improves input use efficiency. Using VRA alongside geo-spatial mapping, farmers can apply inputs to hyper-localized regions of their farm, sometimes down to the individual plant level. Reducing input use lowers costs and lessens negative environmental impacts. Furthermore, empirical evidence indicates precision agriculture technologies can increase yields. On U.S. peanut farms, guidance systems are associated with a 9% increase in yield, and soil maps are associated with a 13% increase in yield. One study in Argentina found that a precision agriculture approach based on crop physiological principles could result in 54% higher farm output. Digital agriculture can improve the allocative efficiency of physical capital within and between farms. Often touted as "Uber for tractors," equipment-sharing platforms like Hello Tractor, WeFarmUp, MachineryLink Solutions, TroTro Tractor, and Tringo facilitate farmer rental of expensive machinery, an on-demand model with parallels to Public transport. These platforms are an example of agricultural Fleet management, often coordinated with Fleet management software. By facilitating a market for equipment sharing, telematics technology ensures fewer tractors sit idle and allows owners to make extra income.
Sources: en.wikipedia.org
However, the restrictive protocol is not an option with some especially vulnerable patients who may require the best possible efforts to rapidly restore tissue oxygenation. Although transfusions of platelets are far less numerous (relative to RBC), platelet storage lesion and resulting efficacy loss is also a concern.
The analysis revealed two mutations in the SH3TC2 gene, which is already known to be associated with CMT. To better understand the inheritance pattern, researchers compared the genome of the affected individual with those of the patient's parents and seven siblings—some of whom had the disease and others who did not. Both parents were found to carry one normal and one mutated copy of the SH3TC2 gene and showed either mild or no symptoms. However, children who inherited two mutated copies of the gene exhibited the full clinical features of the disease.
Under the new instructions, domestic media organizations were told not to report the locations or number of Pakistani airstrikes. On 17 March, the General Directorate of Intelligence (GDI) warned local media outlets not to report casualties among Taliban forces from Pakistani airstrikes, saying that doing so could have serious consequences. Afghan Media Support Organization (AMSO) reported that the Taliban had imposed extensive restrictions on the media, including censorship of security-related events, and restrictions on reporting Taliban casualties. It said that journalists had been forced to publish pro-Taliban reports, including during the border clashes with Pakistan, and that their online activities were being monitored.
Extrapyramidal signs Rhabdomyolysis, acute Ataxia Irregular heart beat Mild hypothyroidism Loss of milestones Delayed speech and language acquisition Delayed walking Abnormal liver enzymes Gastrointestinal dysmotility Generalised brain atrophy High blood ammonia levels Low blood sugar Involuntary muscle contractions Increased lactate in body Prolonged QT interval Seizure Occasional:
The nociceptin opioid peptide receptor (NOP), also known as the nociceptin/orphanin FQ (N/OFQ) receptor or kappa-type 3 opioid receptor, is a protein that in humans is encoded by the OPRL1 (opioid receptor-like 1) gene. The nociceptin receptor is a member of the opioid subfamily of G protein-coupled receptors whose natural ligand is the 17 amino acid neuropeptide known as nociceptin (N/OFQ). This receptor is involved in the regulation of numerous brain activities, particularly instinctive and emotional behaviors. Antagonists targeting NOP are under investigation for their role as treatments for depression and Parkinson's disease, whereas NOP agonists have been shown to act as powerful, non-addictive painkillers in non-human primates. Although NOP shares high sequence identity (~60%) with the ‘classical’ opioid receptors μ-OP (MOP), κ-OP (KOP), and δ-OP (DOP), it possesses little or no affinity for opioid peptides or morphine-like compounds. Likewise, classical opioid receptors possess little affinity towards NOP's endogenous ligand nociceptin, which is structurally related to dynorphin A.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.